Francisco Antunes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1404666/publications.pdf

Version: 2024-02-01

93 papers 4,902 citations

38 h-index 95266 68 g-index

93 all docs 93 docs citations

93 times ranked 4572 citing authors

#	Article	IF	CITATIONS
1	Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids, 2005, 19, 593-601.	2.2	472
2	Subgenotype Analysis of Cryptosporidium Isolates from Humans, Cattle, and Zoo Ruminants in Portugal. Journal of Clinical Microbiology, 2003, 41, 2744-2747.	3.9	461
3	A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1995, 333, 408-413.	27.0	326
4	Changing incidence of central nervous system diseases in the EuroSIDA cohort. Annals of Neurology, 2004, 55, 320-328.	5.3	273
5	Distribution of Cryptosporidium subtypes in humans and domestic and wild ruminants in Portugal. Parasitology Research, 2006, 99, 287-292.	1.6	165
6	A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. Aids, 2003, 17, 987-999.	2.2	151
7	Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (Al424-097) 48-Week Results. Clinical Infectious Diseases, 2007, 44, 1484-1492.	5.8	143
8	The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003. Cancer, 2004, 100, 2644-2654.	4.1	132
9	Relationship between current level of immunodeficiency and nonâ€acquired immunodeficiency syndromeâ€defining malignancies. Cancer, 2010, 116, 5306-5315.	4.1	120
10	Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive HIV Type 1–Infected Patients: Week 48 Results. Journal of Infectious Diseases, 2013, 208, 32-39.	4.0	104
11	Acute kidney injury in patients with sepsis: a contemporary analysis. International Journal of Infectious Diseases, 2009, 13, 176-181.	3.3	91
12	Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load., 2000, 61, 111-116.		89
13	Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naive HIV-1 Patients: The Arten Trial. Antiviral Therapy, 2011, 16, 339-348.	1.0	89
14	Microsporidia as emerging pathogens and the implication for public health: A 10-year study on HIV-positive and -negative patients. International Journal for Parasitology, 2012, 42, 197-205.	3.1	89
15	Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial. Clinical Infectious Diseases, 2006, 43, 1347-1356.	5.8	85
16	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. Aids, 2007, 21, 721-732.	2.2	85
17	Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy. Journal of Clinical Microbiology, 2000, 38, 1370-1374.	3.9	81
18	Hepatitis delta in HIV-infected individuals in Europe. Aids, 2011, 25, 1987-1992.	2.2	79

#	Article	IF	CITATIONS
19	Genotypes of Enterocytozoon bieneusi in Mammals in Portugal. Journal of Eukaryotic Microbiology, 2006, 53, S61-S64.	1.7	74
20	Long-term risk of mortality after acute kidney injury in patients with sepsis: a contemporary analysis. BMC Nephrology, 2010, 11, 9.	1.8	65
21	Identification of Potentially Human-Pathogenic Enterocytozoon bieneusi Genotypes in Various Birds. Applied and Environmental Microbiology, 2006, 72, 7380-7382.	3.1	62
22	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. Aids, 2001, 15, 2385-2395.	2.2	61
23	Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clinical Microbiology and Infection, 2008, 14, 356-362.	6.0	61
24	Acute renal failure in patients with sepsis. Critical Care, 2007, 11, 411.	5.8	59
25	Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. Journal of Antimicrobial Chemotherapy, 2008, 61, 694-698.	3.0	53
26	Changes in use of antiretroviral therapy in regions of Europe over time. Aids, 1998, 12, 2031-2039.	2.2	51
27	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. Journal of Antimicrobial Chemotherapy, 2010, 65, 548-555.	3.0	51
28	20 Years of HIVâ€2 Infection in Portugal: Trends and Changes in Epidemiology. Clinical Infectious Diseases, 2009, 48, 1166-1167.	5.8	50
29	Cell-Associated Viral Burden Provides Evidence of Ongoing Viral Replication in Aviremic HIV-2-Infected Patients. Journal of Virology, 2011, 85, 2429-2438.	3.4	50
30	Population structure of Pneumocystis jirovecii isolated from immunodeficiency virus-positive patients. Infection, Genetics and Evolution, 2010, 10, 192-199.	2.3	49
31	Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice. PLoS ONE, 2013, 8, e70619.	2.5	49
32	Cryptosporidium spp., Giardia duodenalis, Enterocytozoon bieneusi and Other Intestinal Parasites in Young Children in Lobata Province, Democratic Republic of São Tomé and Principe. PLoS ONE, 2014, 9, e97708.	2.5	48
33	<i>Cryptosporidium felis</i> and <i>C. meleagridis</i> in Persons with HIV, Portugal. Emerging Infectious Diseases, 2004, 10, 2256-2257.	4.3	47
34	Baseline susceptibility of primary HIV-2 to entry inhibitors. Antiviral Therapy, 2012, 17, 565-570.	1.0	44
35	Occurrence of Cryptosporidium and Giardiagenotypes and subtypes in raw and treated water in Portugal. Letters in Applied Microbiology, 2009, 48, 732-7.	2.2	43
36	Prognostic utility of RIFLE for acute renal failure in patients with sepsis. Critical Care, 2007, 11, 408.	5.8	42

#	Article	IF	Citations
37	Identification of relevant single-nucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data. Clinical Microbiology and Infection, 2010, 16, 878-884.	6.0	41
38	Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. Aids, 2006, 20, 1141-1150.	2.2	39
39	Occurrence and molecular characterization of Cryptosporidium spp. in mammals and reptiles at the Lisbon Zoo. Parasitology Research, 2005, 97, 108-112.	1.6	38
40	Tuberculosis, a re-emergent disease. European Journal of Radiology, 2005, 55, 154-157.	2.6	37
41	Identification and determination of the viability of Giardia lamblia cysts and Cryptosporidium parvum and Cryptosporidium hominis oocysts in human fecal and water supply samples by fluorescent in situ hybridization (FISH) and monoclonal antibodies. Parasitology Research, 2005, 98, 48-53.	1.6	36
42	Clinical Relevance of Multiple Single-Nucleotide Polymorphisms in Pneumocystis jirovecii Pneumonia: Development of a Multiplex PCR-Single-Base-Extension Methodology. Journal of Clinical Microbiology, 2011, 49, 1810-1815.	3.9	35
43	Acute kidney injury in hospitalized HIV-infected patients: a cohort analysis. Nephrology Dialysis Transplantation, 2011, 26, 3888-3894.	0.7	33
44	Multilocus Genotyping of Cryptosporidium Isolates from Human HIV-Infected and Animal Hosts. Journal of Eukaryotic Microbiology, 2001, 48, 17s-18s.	1.7	31
45	An assessment of the RIFLE criteria for acute renal failure in critically ill HIV-infected patients. Critical Care, 2006, 11, 401.	5.8	31
46	Toxoplasma gondii prevalence in cats from Lisbon and in pigs from centre and south of Portugal. Veterinary Parasitology, 2014, 200, 8-12.	1.8	31
47	Quantitation of Human Immunodeficiency Virus Type 2 DNA in Peripheral Blood Mononuclear Cells by Using a Quantitative-Competitive PCR Assay. Journal of Clinical Microbiology, 1999, 37, 453-456.	3.9	28
48	A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Aids, 1999, 13, 2411-2420.	2.2	26
49	Pneumocystis jiroveci in Portuguese immunocompromised patients: association of specific ITS genotypes with treatment failure, bad clinical outcome and childhood. Infection, Genetics and Evolution, 2003, 3, 281-285.	2.3	25
50	Mutations in the dihydropteroate synthase gene of Pneumocystis jiroveci isolates from Portuguese patients with Pneumocystis pneumonia. International Journal of Antimicrobial Agents, 2003, 22, 516-520.	2.5	24
51	Detection of Pneumocystis jirovecii dihydropteroate synthase polymorphisms in patients with Pneumocystis pneumonia. Scandinavian Journal of Infectious Diseases, 2005, 37, 766-771.	1.5	24
52	The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients. Retrovirology, 2008, 5, 78.	2.0	23
53	Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. Aids, 2012, 26, 2275-2284.	2.2	23
54	Post-Exposure Prophylaxis of HIV Infection in Healthcare Workers: Recommendations for the European Setting. European Journal of Epidemiology, 2003, 19, 577-584.	5.7	22

#	Article	IF	Citations
55	Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal. Journal of Antimicrobial Chemotherapy, 2006, 58, 1246-1249.	3.0	22
56	Microsatellite Analysis of Cryptosporidium hominis and C. parvum in Portugal: a Preliminary Study. Journal of Eukaryotic Microbiology, 2003, 50, 529-530.	1.7	21
57	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 338-340.	2.1	21
58	Microsporidia Detection in Stools from Pets and Animals from the Zoo in Portugal: A Preliminary Study. Journal of Eukaryotic Microbiology, 2003, 50, 581-582.	1.7	20
59	Pneumocystis jirovecii multilocus genotyping in pooled DNA samples: a new approach for clinical and epidemiological studies. Clinical Microbiology and Infection, 2012, 18, E177-E184.	6.0	20
60	Distribution of Cryptosporidium Species and Subtypes in Water Samples in Portugal: A Preliminary Study. Journal of Eukaryotic Microbiology, 2006, 53, S24-S25.	1.7	16
61	Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. Aids, 2008, 22, 2257-2265.	2.2	16
62	Genetic characterization of the UCS and Kex1 loci of Pneumocystis jirovecii. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 175-178.	2.9	16
63	Long-term risk of mortality for acute kidney injury in HIV-infected patients: a cohort analysis. BMC Nephrology, 2013, 14, 32.	1.8	16
64	Tuberculosis with malaria or HIV co-infection in a large hospital in Luanda, Angola. Journal of Infection in Developing Countries, 2013, 7, 269-272.	1.2	16
65	Handling of Fresh Vegetables: Knowledge, Hygienic Behavior of Vendors, Public Health in Maputo Markets, Mozambique. International Journal of Environmental Research and Public Health, 2020, 17, 6302.	2.6	15
66	CRYPTOSPORIDIUM SPP. IN RUMINANTS AT THE LISBON ZOO. Journal of Zoo and Wildlife Medicine, 2003, 34, 352-356.	0.6	13
67	PCR–RFLP analysis of Cryptosporidium parvum isolates from HIV-infected patients in Lisbon, Portugal. Annals of Tropical Medicine and Parasitology, 2000, 94, 291-297.	1.6	12
68	Acute renal failure in critically ill HIV-infected patients. Critical Care, 2007, 11, 404.	5.8	12
69	PCR-RFLP Analysis of the DHPS gene for the Study of Resistance of Pneumocystis carinii to Sulpha Drugs in Patients with Co-infection PCP/HIV. Journal of Eukaryotic Microbiology, 2001, 48, 148s-149s.	1.7	10
70	Diagnostic Use of 3 Techniques for Identification of Microsporidian Spores Among AIDS Patients in Portugal. Scandinavian Journal of Infectious Diseases, 2002, 34, 591-593.	1.5	10
71	Bulk Cytokine Production versus Frequency of Cytokine-Producing Cells in HIV1 Infection before and during HAART. Clinical Immunology, 2000, 97, 162-170.	3.2	9
72	Low CD4 T-cell counts despite low levels of circulating HIV: Insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease. Clinical Immunology, 2007, 125, 67-75.	3.2	9

#	Article	IF	Citations
73	Study of the epidemiology of <i>Pneumocystis carinii </i> f. sp. <i>suis </i> in abattoir swine in Portugal. Medical Mycology, 2013, 51, 66-71.	0.7	9
74	Direct treatment costs of HIV/AIDS in Portugal. Revista De Saude Publica, 2013, 47, 865-872.	1.7	9
75	Atazanavir sulfate + cobicistat for the treatment of HIV infection. Expert Review of Anti-Infective Therapy, 2017, 15, 569-576.	4.4	9
76	Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count?300 cells/?L who were assigned to 7.5 MIU interleukin-2. HIV Medicine, 2007, 8, 112-123.	2.2	7
77	Pneumocystis jirovecii Carriage in Portuguese Immunocompetent Patients: Preliminary Results. Journal of Eukaryotic Microbiology, 2003, 50, 647-648.	1.7	6
78	HIV-2: the Portuguese Connection. Clinical Infectious Diseases, 2004, 39, 1553-1554.	5.8	6
79	Multilocus Genotyping of Pneumocystis jirovecii in Immunocompromised Patients: Preliminary Results. Journal of Eukaryotic Microbiology, 2006, 53, S104-S105.	1.7	6
80	Genetic Diversity and Drug Resistance Profiles in HIV Type 1- and HIV Type 2-Infected Patients from Cape Verde Islands. AIDS Research and Human Retroviruses, 2012, 28, 510-522.	1.1	6
81	Methodology of the Diagnosis of Microsporidiosis in Urine and Pulmonary Specimens from AIDS Patients. Journal of Eukaryotic Microbiology, 2001, 48, 69s-70s.	1.7	5
82	Pneumocystis jirovecii and Pneumocystosis. , 2017, , 215-254.		5
83	A Dose-Ranging Study to Evaluate the Antiretroviral Activity and Safety of Amprenavir Alone and in Combination with Abacavir in HIV-Infected Adults with Limited Antiretroviral Experience. Antiviral Therapy, 2001, 6, 89-96.	1.0	5
84	HIV Infection: Time from Diagnosis to Initiation of Antiretroviral Therapy in Portugal, a Multicentric Study. Healthcare (Switzerland), 2021, 9, 797.	2.0	4
85	Dihydropteroate Synthase (DHPS) Genotyping by PCR-RFLP Analysis of Pneumocystis jirovecii Repeated Isolates from HIV-Infected Patients: A Preliminary Study. Journal of Eukaryotic Microbiology, 2003, 50, 607-608.	1.7	3
86	HIV Infection and Non-tuberculous Mycobacteria: How Important in Southern European Countries?. Scandinavian Journal of Infectious Diseases, 2004, 36, 685-686.	1.5	2
87	Is there a gender shift in HCV infection?. International Journal of Infectious Diseases, 2005, 9, 230-231.	3.3	2
88	The case of the disappearing mycobacteria in Ziehl–Neelsen-stained smears. International Journal of Infectious Diseases, 2011, 15, e291.	3.3	1
89	Antiretroviral therapy for na \tilde{A} -ve and for treatment-experienced HIV patients, and prevention of HIV transmission. Current Opinion in HIV and AIDS, 2011, 6, S1-S2.	3.8	1
90	Towards a Global Perspective of Environmental Health: Defining the Research Grounds of an Institute of Environmental Health. Sustainability, 2020, 12, 8963.	3.2	1

#	Article	IF	CITATIONS
91	Human immunodeficiency virus infection and systolic myocardial performance. International Journal of Angiology, 1994, 3, 148-153.	0.6	0
92	Seroprevalence of SARS-CoV-2 among Health Care Personnel in Portugal., 0, , .		0
93	Recombinant CagA enzyme-linked immunosorbent assay and western immunoblot for the detection of serum antibodies to Helicobacter pylori. Clinical Microbiology and Infection, 2000, 6, 149.	6.0	0